113 related articles for article (PubMed ID: 19246196)
1. 5-Aminomethylbenzimidazoles as potent ITK antagonists.
Riether D; Zindell R; Kowalski JA; Cook BN; Bentzien J; Lombaert SD; Thomson D; Kugler SZ; Skow D; Martin LS; Raymond EL; Khine HH; O'Shea K; Woska JR; Jeanfavre D; Sellati R; Ralph KL; Ahlberg J; Labissiere G; Kashem MA; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Mar; 19(6):1588-91. PubMed ID: 19246196
[TBL] [Abstract][Full Text] [Related]
2. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
[TBL] [Abstract][Full Text] [Related]
3. Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.
Moriarty KJ; Winters M; Qiao L; Ryan D; DesJarlis R; Robinson D; Cook BN; Kashem MA; Kaplita PV; Liu LH; Farrell TM; Khine HH; King J; Pullen SS; Roth GP; Magolda R; Takahashi H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5537-40. PubMed ID: 18819794
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
5. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
[TBL] [Abstract][Full Text] [Related]
6. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
[TBL] [Abstract][Full Text] [Related]
7. Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.
Lyne PD; Aquila B; Cook DJ; Dakin LA; Ezhuthachan J; Ioannidis S; Pontz T; Su M; Ye Q; Zheng X; Block MH; Cowen S; Deegan TL; Lee JW; Scott DA; Custeau D; Drew L; Poondru S; Shen M; Wu A
Bioorg Med Chem Lett; 2009 Feb; 19(3):1026-9. PubMed ID: 19097792
[TBL] [Abstract][Full Text] [Related]
8. Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.
Kopecky DJ; Hao X; Chen Y; Fu J; Jiao X; Jaen JC; Cardozo MG; Liu J; Wang Z; Walker NP; Wesche H; Li S; Farrelly E; Xiao SH; Kayser F
Bioorg Med Chem Lett; 2008 Dec; 18(24):6352-6. PubMed ID: 18993068
[TBL] [Abstract][Full Text] [Related]
9. 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.
Lo HY; Bentzien J; Fleck RW; Pullen SS; Khine HH; Woska JR; Kugler SZ; Kashem MA; Takahashi H
Bioorg Med Chem Lett; 2008 Dec; 18(23):6218-21. PubMed ID: 18930400
[TBL] [Abstract][Full Text] [Related]
10. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.
Uto Y; Ogata T; Harada J; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Deguchi T; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Abe M; Kurikawa N; Kawamura S; Yamato M; Osumi J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4151-8. PubMed ID: 19540759
[TBL] [Abstract][Full Text] [Related]
11. Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.
Das J; Liu C; Moquin RV; Lin J; Furch JA; Spergel SH; Doweyko AM; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2006 May; 16(9):2411-5. PubMed ID: 16481166
[TBL] [Abstract][Full Text] [Related]
12. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.
Uto Y; Ogata T; Kiyotsuka Y; Miyazawa Y; Ueno Y; Kurata H; Deguchi T; Yamada M; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Konishi M; Kurikawa N; Kono K; Osumi J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4159-66. PubMed ID: 19541482
[TBL] [Abstract][Full Text] [Related]
13. Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.
Das J; Furch JA; Liu C; Moquin RV; Lin J; Spergel SH; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Doweyko AM; Kamath A; Zhang H; Marathe P; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
Bioorg Med Chem Lett; 2006 Jul; 16(14):3706-12. PubMed ID: 16682193
[TBL] [Abstract][Full Text] [Related]
14. Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases.
Frazier K; Jazan E; McBride CM; Pecchi S; Renhowe PA; Shafer CM; Taylor C; Bussiere D; He MM; Jansen JM; Lapointe G; Ma S; Vora J; Wiesmann M
Bioorg Med Chem Lett; 2006 Apr; 16(8):2247-51. PubMed ID: 16446087
[TBL] [Abstract][Full Text] [Related]
15. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
[TBL] [Abstract][Full Text] [Related]
16. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
[TBL] [Abstract][Full Text] [Related]
18. 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
Shafer CM; Lindvall M; Bellamacina C; Gesner TG; Yabannavar A; Jia W; Lin S; Walter A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4482-5. PubMed ID: 18672368
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
20. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
Sessions EH; Yin Y; Bannister TD; Weiser A; Griffin E; Pocas J; Cameron MD; Ruiz C; Lin L; Schürer SC; Schröter T; LoGrasso P; Feng Y
Bioorg Med Chem Lett; 2008 Dec; 18(24):6390-3. PubMed ID: 18996009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]